Board of Directors

Board of Directors

The Destiny Pharma Board comprises figures drawn from the pharmaceutical and financial industries.

Sir Nigel Rudd

  • Considerable business experience & renowned ‘Dealmaker’
  • Chairman of BBA Aviation, Meggitt PLC, formerly Chairman of BAA, Invensys & Boots

Neil Clark
Chief Executive Officer

  • 19 years in biotech/life sciences leadership positions
  • Previously CFO/CEO at CeNeS Pharmaceuticals plc and CFO Ergomed plc and CEO at PrimeVigilance

Dr Bill Love
Chief Scientific Officer

  • Founded Destiny Pharma & delivering Company asset base
  • Inventor of XF Drug Series platform

Simon Sacerdoti
Chief Financial Officer

  • Chartered accountant, operational, finance & corporate finance
  • including 12 years at BDO and EY; 5 years as Nomad

Professor David Roblin

  • Former Head of R&D for Pfizer (UK), experience in global anti-infective drugs
  • Ex Head of anti-infectives, Bayer
  • Current COO at the Francis Crick Institute

Joe Eagle

  • Founded PPS & sold to Parexel in 1998; continues to be active in industry
  • Ex Pfizer Marketing

Peter Morgan

  • Founded Beaufort Group in 1987; AIM floated in 1996. Advisor to industry
  • Ex Ciba & Ciba Vision Country Head

David Scott

  • On Board of Biocontrol – reversed into a NASDAQ listed company in 2011
  • Ex Fisons

Howard Matthews

  • Founder of the Cadmus Organisation, specialising in Corporate Finance
  • Ex 3i & Unisys

With many years of experience in drug development and commercialisation, the Destiny Pharma directors possess the expertise required to successfully manage the company and develop its portfolio of products.